RXRX Recursion Pharmaceuticals, Inc. Class A Common Stock Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
18:44
Oct 06
Martin Shkreli
Short AI drug dev plays pre-IND
Short Recursion Pharmaceuticals as an explicit recommendation: the speaker's bear case is that AI-platform drug discovery narratives avoid the expensive, dilutive IND-enabling tox step where real VCs tighten valuations.
RXRX Recursion Pharmaceuticals, Inc. Class A Common Stock Short — —
18:07
Oct 05
Martin Shkreli
Short AI drug devs on tox costs
Short Recursion Pharmaceuticals within the AI drug development basket; the expensive tox and clinical steps will reveal which companies merit VC funding and premium valuations.
RXRX Recursion Pharmaceuticals, Inc. Class A Common Stock Short — —
16:26
Oct 05
Martin Shkreli
Short RXRX on broken AI drug model
Short RXRX because Shkreli argues its AI-driven drug discovery tools cannot replace translational judgment in selecting good medicines, making the company a persistent "dumpster fire."
RXRX Recursion Pharmaceuticals, Inc. Class A Common Stock Short 1ST — —
Log in to see ideas

About RXRX Investor Commentary

Across the available history and selected sources, Buzzberg tracks RXRX (Recursion Pharmaceuticals, Inc. Class A Common Stock) across 19 sources: 10 bullish vs 3 bearish calls from 24 authors. Historical directional balance: 16% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 43 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: Martin Shkreli.